ArticleThe Lancet. Oncology2020

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.

Jonathan A Ledermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.